XML 35 R26.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2024
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue by Product and by Geographic Area | Revenues were as follows (in millions):
|  | Three months ended March 31,
|  | 2024 |  | 2023
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 657 |  |  | $ | 342 |  |  | $ | 999 |  |  | $ | 623 |  |  | $ | 304 |  |  | $ | 927 |
ENBREL |  | 561 |  |  | 6 |  |  | 567 |  |  | 564 |  |  | 15 |  |  | 579 |
XGEVA |  | 366 |  |  | 195 |  |  | 561 |  |  | 384 |  |  | 152 |  |  | 536 |
Repatha |  | 273 |  |  | 244 |  |  | 517 |  |  | 197 |  |  | 191 |  |  | 388 |
TEPEZZA(1) |  | 419 |  |  | 5 |  |  | 424 |  |  | — |  |  | — |  |  | — |
Otezla |  | 293 |  |  | 101 |  |  | 394 |  |  | 294 |  |  | 98 |  |  | 392 |
KYPROLIS |  | 234 |  |  | 142 |  |  | 376 |  |  | 234 |  |  | 124 |  |  | 358 |
Aranesp |  | 100 |  |  | 249 |  |  | 349 |  |  | 115 |  |  | 240 |  |  | 355 |
EVENITY |  | 236 |  |  | 106 |  |  | 342 |  |  | 164 |  |  | 90 |  |  | 254 |
Nplate |  | 190 |  |  | 127 |  |  | 317 |  |  | 246 |  |  | 116 |  |  | 362 |
Vectibix |  | 120 |  |  | 127 |  |  | 247 |  |  | 111 |  |  | 122 |  |  | 233 |
BLINCYTO |  | 153 |  |  | 91 |  |  | 244 |  |  | 126 |  |  | 68 |  |  | 194 |
KRYSTEXXA(1) |  | 235 |  |  | — |  |  | 235 |  |  | — |  |  | — |  |  | — |
TEZSPIRE(2) |  | 173 |  |  | — |  |  | 173 |  |  | 96 |  |  | — |  |  | 96 |
Other products(3) |  | 963 |  |  | 410 |  |  | 1,373 |  |  | 821 |  |  | 351 |  |  | 1,172 |
Total product sales(4) |  | $ | 4,973 |  |  | $ | 2,145 |  |  | 7,118 |  |  | $ | 3,975 |  |  | $ | 1,871 |  |  | 5,846 |
Other revenues |  |  |  |  |  | 329 |  |  |  |  |  |  | 259 |
Total revenues |  |  |  |  |  | $ | 7,447 |  |  |  |  |  |  | $ | 6,105 |
____________ (1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date. (2) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States. (3) Consists of product sales of our non-principal products. (4) Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2024 and 2023.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration